Pharma BD Deal Intelligence
Grifols to acquire a Novartis diagnostics business unit for US$1,675 million, expanding its transfusion diagnostics footprint.
Grifols's SEC 6-K confirmed close of the Novartis Diagnostics acquisition for $1.675B, lifting the diagnostics division from ~4% to >20% of total company sales…
MassDevice traced the Procleix franchise lineage — Grifols's 2014 purchase of Novartis's transfusion diagnostics unit set up the eventual 2016 buyout of…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Grifols agreed to acquire Novartis's blood-transfusion diagnostics unit for $1.675B; expected to bring Grifols Diagnostic Division to >20% of company sales (~$1B turnover).
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Grifols, S.A. / Novartis Diagnostics (blood transfusion unit) (this deal) | 2013 | $1.7B | 46 |
| Grifols, S.A. / Talecris Biotherapeutics Holdings Corp. | 2011 | $3.4B | 68 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
← Browse all deals · How we score deals
More: 2013 deals · Other deals